Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 18, Issue , 2016, Pages 17-24

  Mudaliar, S ^a,b   Henry, R R ^a,b   Ciaraldi, T P ^a,b   Armstrong, D A ^a   Burke, P M ^a   Pettus, J H ^b   Garhyan, P ^c   Choi, S L ^d   Knadler, M P ^c   Lam, E C Q ^d   Prince, M J ^c   Bose, N ^b   Porksen, N K ^c   Sinha, V P ^c,e   Linnebjerg, H ^c   Jacober, Scott J ^c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Eli Lilly Singapore Pte Ltd   (Singapore)

^e American Diabetes Association   (United States)

Author keywords

basal insulin; clinical trial; drug development; pharmacodynamics; phase III study

Indexed keywords

FATTY ACID; GLUCOSE; GLYCEROL; INSULIN GLARGINE; INSULIN PEGLISPRO; ANTIDIABETIC AGENT; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; INSULIN LISPRO; MACROGOL DERIVATIVE; TRITIUM;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FATTY ACID BLOOD LEVEL; FEMALE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE DISPOSAL RATE; GLUCOSE METABOLISM; GLYCEROL BLOOD LEVEL; HEPATOPREFERENTIAL ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPOLYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN GLARGINE; INSULIN LISPRO; LIPOLYSIS; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TRITIUM; YOUNG ADULT;

EID: 84990228019     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12753     Document Type: Article

References (23)

1. Eaton RP, Allen RC, Schade DS, Standfer JC. “Normal” insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care. 1980;3:270–273.
2. De Vos P, De Haan BJ, Vegter D, et al. Insulin levels after portal and systemic insulin infusion differ in a dose-dependent fashion. Horm Metab Res. 1998;30:721–725.
3. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54:1649–1656.
4. Edgerton DS, Lautz M, Scott M, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116:521–527.
5. Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab. 2014;16:1–8.
6. Gregory JM, Kraft G, Scott MF, et al. Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64:3439–3451.
7. Sinha VP, Choi SL, Soon DK, et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol. 2014;54:792–799.
8. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140–2147.
9. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–528.
10. Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro versus insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1 study. Diabetes Obes Metab. 2016;18(S2):25–33.
11. Davies MJ, Russell-Jones D, Selam J-L, et al. Double-blind comparison of basal insulin peglispro and insulin glargine in insulin-naive patients with type 2 diabetes: the IMAGINE 2 clinical trial. Diabetes Obes Metab. 2016;18:1054–1063.
12. Bergenstal RM, Lunt H, Franek E, et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1080–1087.
13. Blevins T, Pieber TR, Vega G, Zhang S, Bastyr E Jr, Chang AM. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab. 2016;18:1071–1079.
14. Buse JB, Rodbard HW, Trescoli-Serrano C, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39:92–100.
15. Grunberger G, Chen L, Rodriguez A, Tinahones FJ, Jacober SJ, Bue-Valleskey J. A randomized clinical trial of basal insulin peglispro versus NPH in insulin-naive patients with type 2 diabetes: IMAGINE 6. Diabetes Obes Metab. 2016;18(S2):34–42.
16. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals JM. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes Metab. 2014;16:351–356.
17. Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63:494–504.
18. Henry RR, Mudaliar S, Ciaraldi TP, et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes. 2014;63(Suppl. 1):A226.
19. Mudaliar S, Mohideen P, Deutsch R, et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care. 2002;25:1597–1602.
20. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987;36:914–924.
21. Owens RA, Hansen RJ, Kahl SD, et al. In vivo and in vitro characterization of basal insulin peglispro: a novel insulin analogue. J Pharmacol Exp Ther. 2016;375:459–465.
22. Cusi K, Sanyal A, Zhang S, Hoogwerf BJ, Chang AM. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab. 2016;18(S2):50–58.
23. Ginsberg H, Cariou B, Orchard T, et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab. 2016;18:1088–1091.